Sitagliptin as an Initial Therapy and Differential Regulations of Metabolic Parameters Depending on its Glycemic Response in Subjects with Type 2 Diabetes
Drug Res (Stuttg) DOI: 10.1055/a-1304-3430The aim of this study is to investigate whether sitagliptin can be used as an
initial drug for T2DM and to evaluate its effects on metabolic parameters in
relation to its glycemic efficacies. The subjects received
25−50 mg/day sitagliptin monotherapy (n=69).
At 3 months, they were divided into three groups (n=23 each)
according to the novel parameter called “A1c index” which is
designed to assess glycemic efficacy. The metabolic parameters were compared
between good-responders and poor-responders. These two groups acted as a
control each other. In the overall subjects, efficient reductions of HbA1c
(10.16–8.22%) were observed with few adverse events.
Significant correlations were seen between the A1c index and changes of
(∆)nonHDL-C (R=0.250) or ∆LDL-C (R=0.368).
At baseline, T-C, nonHDL-C and BMI levels were significantly lower in
good-responders than poor-responders. At 3 months, in good-responders, HbA1c
levels effectively decreased (11.03–7.00%). Indexes for
insulin sensitivity/resistance [HOMA-R and 20/(C-peptide x
FBG)] and beta-cell function (HOMA-B and CPR-index) ameliorated. T-C,
nonHDL-C and LDL-C significantly decreased, while BMI increased. However, in
poor-responders, no changes in these parame...
Source: Drug Research - Category: Drugs & Pharmacology Authors: Kutoh, Eiji Kuto, Alexandra N. Wada, Askuka Hayashi, Jyunka Kurihara, Rumi Tags: Original Article Source Type: research
More News: Cholesterol | Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Insulin | Januvia | Study